Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%

Orthofix Medical Inc.

2025-Q3 EPS reported -$2.28 revenue$602,401,000

Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.
Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.
U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.
FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.
Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.